<info type="SequenceVariant">Mutation</info> analysis of <info type="GeneOrGeneProduct">CHRNA1</info>, <info type="GeneOrGeneProduct">CHRNB1</info>, <info type="GeneOrGeneProduct">CHRND</info>, and <info type="GeneOrGeneProduct">RAPSN</info> genes in multiple <info type="DiseaseOrPhenotypicFeature">pterygium syndrome</info>/<info type="DiseaseOrPhenotypicFeature">fetal akinesia</info> patients.

Multiple <info type="DiseaseOrPhenotypicFeature">pterygium syndromes</info> (<info type="DiseaseOrPhenotypicFeature">MPS</info>) comprise a group of multiple congenital anomaly disorders characterized by webbing (<info type="DiseaseOrPhenotypicFeature">pterygia</info>) of the neck, elbows, and/or knees and joint contractures (<info type="DiseaseOrPhenotypicFeature">arthrogryposis</info>). <info type="DiseaseOrPhenotypicFeature">MPS</info> are phenotypically and genetically heterogeneous but are traditionally divided into prenatally lethal and nonlethal (<info type="DiseaseOrPhenotypicFeature">Escobar</info>) types. Previously, we and others reported that recessive <info type="SequenceVariant">mutations</info> in the embryonal acetylcholine receptor <info type="GeneOrGeneProduct">g subunit</info> (<info type="GeneOrGeneProduct">CHRNG</info>) can cause both lethal and nonlethal <info type="DiseaseOrPhenotypicFeature">MPS</info>, thus demonstrating that <info type="DiseaseOrPhenotypicFeature">pterygia</info> resulted from <info type="DiseaseOrPhenotypicFeature">fetal akinesia</info>. We hypothesized that <info type="SequenceVariant">mutations</info> in acetylcholine receptor-related genes might also result in a <info type="DiseaseOrPhenotypicFeature">MPS</info>/<info type="DiseaseOrPhenotypicFeature">fetal akinesia</info> phenotype and so we analyzed 15 cases of lethal <info type="DiseaseOrPhenotypicFeature">MPS</info>/<info type="DiseaseOrPhenotypicFeature">fetal akinesia</info> without <info type="GeneOrGeneProduct">CHRNG</info> <info type="SequenceVariant">mutations</info> for <info type="SequenceVariant">mutations</info> in the <info type="GeneOrGeneProduct">CHRNA1</info>, <info type="GeneOrGeneProduct">CHRNB1</info>, <info type="GeneOrGeneProduct">CHRND</info>, and <info type="GeneOrGeneProduct">rapsyn</info> (<info type="GeneOrGeneProduct">RAPSN</info>) genes. No <info type="GeneOrGeneProduct">CHRNA1</info>, <info type="GeneOrGeneProduct">CHRNB1</info>, or <info type="GeneOrGeneProduct">CHRND</info> <info type="SequenceVariant">mutations</info> were detected, but a homozygous <info type="GeneOrGeneProduct">RAPSN</info> <info type="SequenceVariant">frameshift mutation</info>, <info type="SequenceVariant">c.1177-1178delAA</info>, was identified in a family with three children affected with lethal <info type="DiseaseOrPhenotypicFeature">fetal akinesia</info> <info type="SequenceVariant">sequence</info>. Previously, <info type="GeneOrGeneProduct">RAPSN</info> <info type="SequenceVariant">mutations</info> have been reported in <info type="DiseaseOrPhenotypicFeature">congenital myasthenia</info>. Functional studies were consistent with the hypothesis that whereas incomplete loss of <info type="GeneOrGeneProduct">rapsyn</info> function may cause <info type="DiseaseOrPhenotypicFeature">congenital myasthenia</info>, more severe loss of function can result in a lethal <info type="DiseaseOrPhenotypicFeature">fetal akinesia</info> phenotype.